Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives $21.00 Average PT from Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has earned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $20.40.

Several research analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Royal Bank Of Canada cut Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday. Citigroup lowered their target price on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Finally, Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th.

Telix Pharmaceuticals Trading Down 3.4%

TLX opened at $10.46 on Wednesday. The company’s 50 day moving average is $10.36 and its 200 day moving average is $9.06. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $16.94.

Insider Activity at Telix Pharmaceuticals

In related news, CEO Christian Behrenbruch acquired 34,500 shares of the stock in a transaction dated Tuesday, April 28th. The shares were purchased at an average cost of $14.48 per share, with a total value of $499,560.00. Following the transaction, the chief executive officer directly owned 20,709,500 shares in the company, valued at approximately $299,873,560. This represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Telix Pharmaceuticals during the 4th quarter valued at $89,000. XY Capital Ltd purchased a new position in shares of Telix Pharmaceuticals during the 1st quarter valued at $120,000. Finally, IHT Wealth Management LLC purchased a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.